Spero Therapeutics stock hits 52-week high at $2.53
- Investing.com
- English (USA)
- English (UK)
- English (India)
- English (Canada)
- English (Australia)
- English (South Africa)
- English (Philippines)
- Deutsch
- Español (España)
- Español (México)
- Français
- Italiano
- Nederlands
- Português (Portugal)
- Polski
- Português (Brasil)
- Русский
- Türkçe
- العربية
- Ελληνικά
- Svenska
- Suomi
- עברית
- 日本語
- 한국어
- 简体中文
- 繁體中文
- Bahasa Indonesia
- Bahasa Melayu
- ไทย
- Tiếng Việt
- हिंदी
Spero Therapeutics Inc (SPRO)
Spero Therapeutics Inc stock price live, this page displays NASDAQ SPRO stock exchange data. View the SPRO premarket stock price ahead of the market session or assess the after hours quote. Monitor the latest movements within the Spero Therapeutics Inc real time stock price chart below.
What Is the Spero Therapeutics Inc Stock Price Today?
The Spero Therapeutics Inc stock price today is 2.170.
What Is the Stock Symbol for Spero Therapeutics Inc?
The stock symbol for Spero Therapeutics Inc is ""SPRO.""
What Stock Exchange Does Spero Therapeutics Inc Trade On?
Spero Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Spero Therapeutics Inc a Good Stock to Buy?
Determining whether Spero Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRO quote. (ISIN: US84833T1034)
What Is the Spero Therapeutics Inc Stock Price Today?
The Spero Therapeutics Inc stock price today is 2.170.
What Is the Stock Symbol for Spero Therapeutics Inc?
The stock symbol for Spero Therapeutics Inc is ""SPRO.""
What Stock Exchange Does Spero Therapeutics Inc Trade On?
Spero Therapeutics Inc is listed and trades on the NASDAQ stock exchange.
Is Spero Therapeutics Inc a Good Stock to Buy?
Determining whether Spero Therapeutics Inc—or any stock—is a good buy requires comprehensive analysis. To evaluate its potential, users can sign up to InvestingPro, where they can assess stock price fair value and other essential metrics.
You can find more details by visiting the additional pages to view historical data, charts, latest news, analysis or visit the forum to view opinions on the SPRO quote. (ISIN: US84833T1034)
NASDAQ
Currency in USD
2.170
-0.090(-3.98%)
Closed·
After Hours
2.1700.000(0.00%)
·
Fair Value
An estimate of a Spero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.125
2.270
52 wk Range
0.505
3.220
SPRO Scorecard
Full Analysis
Holds more cash than debt on its balance sheet
Earnings results expected in 4 days
1/2
Fair Value
An estimate of a Spero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Day's Range
2.1252.270
52 wk Range
0.5053.220
Key Statistics
Edit
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
Prev. Close
Open
Volume
Average Volume (3m)
1-Year Change
Book Value / Share
Fair Value
UnlockFair Value Upside
UnlockMarket Cap
Shares Outstanding
Revenue
Net Income
EPS
EPS Growth Forecast
UnlockNext Earnings Date
N/A
(N/A)
Dividends Payment Streak
UnlockP/E Ratio
Return on Assets
Return on Equity
Gross Profit Margin
Price/Book
EBITDA
EV/EBITDA
Beta
SPRO Scorecard
Company’s Health
Assesses a company's financial position by analysing its market value, financial ratios, industry benchmarks, and competitors.
UnlockFair Value
An estimate of a Spero Therapeutics's true price based on valuation models like discounted cash flow, peer valuation multiples, and dividend discount models.
Unlock PriceTechnical Analysis
Strong Sell
Analysts Sentiment
Neutral
Price Target
5.000
Upside
+130.41%
Members' Sentiments
Bearish
Bullish
ProTips
Tips that distill complex financial data into concise, actionable investment insights.
Analysts anticipate sales decline in the current year
- Form 8K Spero Therapeutics Inc For: 28 May
- Investing.com
- Spero Therapeutics stock hits 52-week high at $2.53
- Investing.com
- Form 8K Spero Therapeutics Inc For: 28 May
- Investing.com
Technical Analysis
Summary
Strong Sell
Sell
Neutral
Buy
Strong Buy
Strong Sell
Technical Indicators
Strong Sell
Moving Averages
Sell
Spero Therapeutics Inc Company Profile
Spero Therapeutics, Inc., a clinical-stage biopharmaceutical company, focuses on identifying and developing novel treatments for multi-drug resistant (MDR) bacterial infections and rare diseases in the United States. The company’s product candidates include Tebipenem HBr (tebipenem pivoxil hydrobromide), an oral carbapenem-class antibiotic to treat complicated urinary tract infections, including pyelonephritis for adult patients, which is in Phase 3 development; and SPR720, a novel product candidate for first-line treatment of nontuberculous mycobacterial (NTM) pulmonary disease. It has license agreement with Meiji Seika Pharma Co., Ltd. to support the development of tebipenem HBr; Everest Medicines to develop, manufacture, and commercialize SPR206 in Greater China, South Korea, and Southeast Asian countries; and Vertex Pharmaceuticals Incorporated for patents relating to the oral prodrug SPR720, as well as SPR719, an active metabolite. Spero Therapeutics, Inc. was founded in 2013 and is headquartered in Cambridge, Massachusetts.
Spero Therapeutics Inc Earnings Call Summary for Q4/2024
- Q4 2024 revenue of $15M exceeded forecast, but EPS of -$0.38 missed expectations; stock fell 1.48% in regular trading and 4.39% after hours
- Cash runway extended to Q2 2026 due to $47.5M GSK milestone payment; company maintains strong financial health with 3.19/5 score
- Development of SPR-720 discontinued due to safety concerns; focus shifts to advancing Tebipenem HBR with Phase III interim analysis in Q2 2025
- Full-year 2024 revenue decreased to $48M from $103.8M in 2023; R&D expenses increased to $97M, potentially straining resources
- Company exploring potential milestone payments from GSK, contingent on successful submission of new drug application for Tebipenem HBR
Last Updated: 27/03/2025, 22:26
Read Full TranscriptCompare SPRO to Peers and Sector
Metrics to compare | SPRO | Sector Sector - Average of metrics from a broad group of related Healthcare sector companies | Relationship RelationshipSPROPeersSector | |
|---|---|---|---|---|
P/E Ratio | −1.8x | −1.1x | −0.5x | |
PEG Ratio | 0.00 | −0.06 | 0.00 | |
Price/Book | 3.7x | 2.2x | 2.6x | |
Price / LTM Sales | 2.8x | 9.2x | 3.3x | |
Upside (Analyst Target) | 121.2% | 307.6% | 43.4% | |
Fair Value Upside | Unlock | 18.5% | 7.1% | Unlock |
Analyst Ratings
0 Buy
2 Hold
0 Sell
Ratings:
2 analysts
Overall Consensus
Neutral
Analysts 12-Month Price Target:
Average 5.000
(+130.41% Upside)
Earnings
Latest Release
May 13, 2025
EPS / Forecast
-0.25 / -0.27
Revenue / Forecast
5.87M / 11.00M
People Also Watch
FAQ
What Stock Exchange Does Spero Therapeutics Trade On?
Spero Therapeutics is listed and trades on the Nasdaq Stock Exchange stock exchange.
What Is the Stock Symbol for Spero Therapeutics?
The stock symbol for Spero Therapeutics is "SPRO."
What Is the Spero Therapeutics Market Cap?
As of today, Spero Therapeutics market cap is 121.05M.
What Is Spero Therapeutics's Earnings Per Share (TTM)?
The Spero Therapeutics EPS (TTM) is -1.28.
When Is the Next Spero Therapeutics Earnings Date?
Spero Therapeutics will release its next earnings report on 11 Aug 2025.
From a Technical Analysis Perspective, Is SPRO a Buy or Sell?
Based on moving averages and other technical indicators, the daily buy/sell signal is Strong Sell.
How Many Times Has Spero Therapeutics Stock Split?
Spero Therapeutics has split 0 times.
How Many Employees Does Spero Therapeutics Have?
Spero Therapeutics has 32 employees.
What is the current trading status of Spero Therapeutics (SPRO)?
As of 07 Aug 2025, Spero Therapeutics (SPRO) is trading at a price of 2.17, with a previous close of 2.26. The stock has fluctuated within a day range of 2.13 to 2.27, while its 52-week range spans from 0.51 to 3.22.
Install Our App
Risk Disclosure: Trading in financial instruments and/or cryptocurrencies involves high risks including the risk of losing some, or all, of your investment amount, and may not be suitable for all investors. Prices of cryptocurrencies are extremely volatile and may be affected by external factors such as financial, regulatory or political events. Trading on margin increases the financial risks.
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
Before deciding to trade in financial instrument or cryptocurrencies you should be fully informed of the risks and costs associated with trading the financial markets, carefully consider your investment objectives, level of experience, and risk appetite, and seek professional advice where needed.
Fusion Media would like to remind you that the data contained in this website is not necessarily real-time nor accurate. The data and prices on the website are not necessarily provided by any market or exchange, but may be provided by market makers, and so prices may not be accurate and may differ from the actual price at any given market, meaning prices are indicative and not appropriate for trading purposes. Fusion Media and any provider of the data contained in this website will not accept liability for any loss or damage as a result of your trading, or your reliance on the information contained within this website.
It is prohibited to use, store, reproduce, display, modify, transmit or distribute the data contained in this website without the explicit prior written permission of Fusion Media and/or the data provider. All intellectual property rights are reserved by the providers and/or the exchange providing the data contained in this website.
Fusion Media may be compensated by the advertisers that appear on the website, based on your interaction with the advertisements or advertisers
© 2007-2025 - Fusion Media Limited. All Rights Reserved.